Stockscreener 앱 받기
2.15
4.87%
-0.11
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne - GlobeNewswire Inc.
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo! Finance Canada
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo Finance
OVID Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com
H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com Nigeria
Ovid Therapeutics (NasdaqCM:OVID) Stock Forecast & Analyst Predictions - Simply Wall Street
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus By Investing.com - Investing.com Canada
Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus - Investing.com
Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us
September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - RTTNews
Ovid management has two September talks scheduled - Stock Titan
Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Ovid (OVID) Shares: Posts a 2.19% Gain to $2.80; Range Check: the Supplied Trading Band Runs From $2.66 to $2.94 in the Latest ReadingDividend ETF - vinanet.vn
Ovid (OVID) Momentum: Finishes 2.19% Higher at $2.80 at the Close; Range View: Traders Can Monitor the $2.66-$2.94 Range in the Current UpdateDeath Cross - vinanet.vn
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus
Ovid (OVID) Quarterly Figures: EPS Prints Above Forecast in the Latest Reading; Investor Response: The Share Price Adds 1.94% in Latest TradingProfit Inflection Point - vinanet.vn
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
OVID Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 1.07%Earnings Acceleration Picks - vinanet.vn
Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen - marketbeat.com
Morgan Stanley (OVID) investor files to sell 150,000 shares valued at $420,000 - Stock Titan
Ovid Therapeutics (OVID) investor reports 9.6M-share beneficial stake - Stock Titan
RA Capital reports 9.99% Ovid Therapeutics stake (OVID) via stock and warrants - Stock Titan
Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics - Stock Titan
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Ovid Therapeutics (OVID) sees 4.99% beneficial stake reported by Balyasny group - Stock Titan
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap - Stock Titan
Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Price Up 9% Following Better-Than-Expected Earnings - MarketBeat
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com
Ovid Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Ovid Therapeutics Inc. (OVID) Latest Stock News & Headlines - Yahoo Finance
OVID: Advanced pipeline, strong cash runway, and soticlestat monetization drive future growth - TradingView
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OVID: Advanced pipeline, strong cash reserves, and expanded leadership drive long-term growth - TradingView
Ovid Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
OVID Looks 59.6% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Ovid Therapeutics Inc. Q2 2026: Revenue $0.7M, EPS $(0.08) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
4.22%
자본화:
|
볼륨(24시간):